These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11598423)

  • 21. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor.
    Haskel EJ; Torr SR; Day KC; Palmier MO; Wun TC; Sobel BE; Abendschein DR
    Circulation; 1991 Aug; 84(2):821-7. PubMed ID: 1860224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
    Feigen LP; Nicholson NS; King LW; Campion JG; Tjoeng FS; Panzer-Knodle SG
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1191-7. PubMed ID: 8263779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries: role of adenosine.
    Hata K; Whittaker P; Kloner RA; Przyklenk K
    Circulation; 1998 Feb; 97(7):692-702. PubMed ID: 9495306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW; Nicolini FA; Khan S; Saldeen TG; Mehta JL
    Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.
    Martin U; Sponer G; König R; Smolarz A; Meyer-Sabellek W; Strein K
    Blood Coagul Fibrinolysis; 1992 Apr; 3(2):139-47. PubMed ID: 1606285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
    Rübsamen K; Hornberger W
    Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis.
    Martin U; Sponer G; Strein K
    Int J Hematol; 1992 Oct; 56(2):143-53. PubMed ID: 1421176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
    Tomaru T; Uchida Y; Sonoki H; Tsukamoto M; Sugimoto T
    Angiology; 1989 May; 40(5):429-35. PubMed ID: 2495745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
    Higo K; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
    Hong TT; Driscoll EM; White AJ; Sherigill A; Giboulot TA; Lucchesi BR
    J Pharmacol Exp Ther; 2003 Aug; 306(2):616-23. PubMed ID: 12734394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhaled nitric oxide increases coronary artery patency after thrombolysis.
    Adrie C; Bloch KD; Moreno PR; Hurford WE; Guerrero JL; Holt R; Zapol WM; Gold HK; Semigran MJ
    Circulation; 1996 Oct; 94(8):1919-26. PubMed ID: 8873669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
    Mellott MJ; Connolly TM; York SJ; Bush LR
    Thromb Haemost; 1990 Dec; 64(4):526-34. PubMed ID: 2128137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thromboxane antagonism in experimental canine carotid artery thrombosis.
    Rote WE; Mu DX; Lucchesi BR
    Stroke; 1993 Jun; 24(6):820-7; discussion 827-8. PubMed ID: 8506554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variability of coronary blood flow reserve assessed by Doppler catheter after successful thrombolysis in patients with acute myocardial infarction.
    Crea F; Davies G; Crake T; Gaspardone A; Galassi A; Kaski JC; Maseri A
    Am Heart J; 1993 Jun; 125(6):1547-52. PubMed ID: 8498292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
    Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T
    Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis.
    Jackson CV; Frank JD; Craft TJ; Sundboom JL; Smith GF
    J Pharmacol Exp Ther; 1992 Jan; 260(1):64-70. PubMed ID: 1731052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury.
    Hennan JK; Hong TT; Shergill AK; Driscoll EM; Cardin AD; Lucchesi BR
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1151-6. PubMed ID: 12023550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
    Kawasaki T; Sato K; Hirayama F; Koshio H; Taniuchi Y; Matsumoto Y
    Thromb Haemost; 1998 Apr; 79(4):859-64. PubMed ID: 9569205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.